Another study observed lower odds of dementia (OR 0.58; 95% CI 0.50, 0.67) with GLP-1RAs, which was proportional to daily dosage, in 11 619 cases of dementia and 46 476 controls from the Danish National Diabetes Register between 1995 and 2012 and followed up until 2018—notably, the same applied to all other antidiabetics (ie, metformin, dipeptidyl peptidase-4 inhibitors (DPP-4i), sodium-glucose co-transporter-2 inhibitors (SGLT-2i)) included in the analysis.53 Here, DPP4 is linked to dementia.